SciSparc Ltd.
SPRC
$4.32
-$0.04-0.92%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/16/2026
-
TipRanks Financial Blog
3/16/2026
-
TipRanks Financial Blog
3/16/2026
-
Globe Newswire
3/13/2026
-
Globe Newswire
3/12/2026
-
TipRanks Financial Blog
3/12/2026
-
TipRanks Financial Blog
3/12/2026
-
Globe Newswire
3/10/2026
-
TipRanks Financial Blog
3/10/2026
-
The Fly
3/10/2026
-
Globe Newswire
3/10/2026
-
Globe Newswire
3/4/2026
-
TipRanks Financial Blog
3/4/2026
-
The Fly
3/3/2026
-
Yahoo! Finance: News
3/2/2026
-
The Fly
3/2/2026
-
The Fly
3/2/2026
-
Globe Newswire
2/17/2026
-
The Fly
2/12/2026
-
TipRanks Financial Blog
2/3/2026
-
The Fly
2/2/2026
-
The Fly
2/2/2026
-
Globe Newswire
1/26/2026
-
GuruFocus
1/26/2026
-
GuruFocus
1/26/2026
-
The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
--
Total Debt (Q)
Total Liabilities (Q)
--
Book Value Per Share (Q)
--
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, November 20, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Apr 20 and 24 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
972 7 334 47180
Address
Tower A
2nd Floor - 20 Raul Wallenberg Street
Tel Aviv-Yafo, 6971916
2nd Floor - 20 Raul Wallenberg Street
Tel Aviv-Yafo, 6971916
Country
Year Founded
Business Description
Sector
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and...
more